Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

Patients don’t take their medicines because they don’t want to Debra is late getting up for work again. In her heart of ...

Bayer’s initiative reflects a broader effort to address the high unmet medical need in oncology. The trial’s success could ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial ...

iOnctura has announced promising results from the phase 1 DIONE-01 study, showcasing the clinical activity and long-term ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS trial for ...

CatalYm has announced promising new data on its lead drug candidate, visugromab, at the 17th International Conference on ...

New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for its ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

The positive pre-clinical results underpin the development of POLB 001 for Phase 2 clinical trials as a prophylactic for ...

Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...

Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...